Newsletter

Tech Stocks

Test text

Droneshield’s Back on Investors Radar, But Who’s Really Flying It?

Droneshield Takes Off Again Droneshield (ASX: DRO) shares jumped 16.2% to close at A$2.26, marking a strong rebound after a period of controversy that had weighed on sentiment. The move has sparked plenty of discussion among investors. Is this the start of institutional money rotating back in, or are traders simply taking advantage of short-term…

ByCharlie YouldenDecember 11, 2025

4DMedical’s Growth Story Gains Airflow in the US Market

4DMedical Finds Its Rhythm 4DMedical (ASX:4DX) climbed 9% today as the company continues to build strong commercial momentum with its CT:VQ lung imaging technology. Following FDA clearance in September, 4DMedical’s entry into the US market is beginning to gain real traction. The latest partnership with the University of Miami adds another major institution to its…

ByCharlie YouldenDecember 10, 2025

OpenAI AI Crown Is No Longer Untouchable

OpenAI’s Reign Faces Its First Real Test Many people have heard the headlines claiming that OpenAI is calling a code red, but most still do not understand why. When we dig into the data on market share across AI model usage, a clearer picture starts to form. What investors and users should keep in mind…

ByCharlie YouldenDecember 10, 2025

Cogstate (ASX:CGS) Sells Off 22% on Timing Delay, But the Fundamentals Stay Intact

Cogstate’s H1 Hit Is a Timing Story, Not a Demand Story Cogstate Ltd (ASX:CGS) delivered a business update this morning that reset expectations for its H1 FY26 revenue timing and margin outlook, which triggered a sharp 22% sell-off. The market reacted to near-term revenue being pushed into the back half of the year due to…

ByCharlie YouldenDecember 10, 2025

PWR Holdings Gets New Leadership: What It Means for Investors After a Tough FY25

PWR Holdings backs internal leader for next phase PWR Holdings (ASX: PWH) announced yesterday that Chief Financial Officer Sharyn Williams will become its next CEO and Managing Director, marking a significant leadership transition for the high-tech cooling solutions company. Williams, who joined as CFO in January 2025, will take over once a replacement is found,…

ByUjjwal MaheshwariDecember 10, 2025

Nvidia’s Back in China, But Uncle Sam Takes a 25% Cut

NVDA Re-enters China Under New Rules President Trump has announced that the US will allow Nvidia to export its H200 chips to approved customers in China, signalling a possible softening of export controls. The move comes with a catch. The US government will collect a 25% fee on every chip sold, and more advanced Blackwell…

ByCharlie YouldenDecember 9, 2025

Netflix Thought It Had the Ending, Paramount Just Wrote a Plot Twist

From Binge to Battle The Warner Bros Discovery (NSDQ:WBD) acquisition saga has escalated into a high-stakes bidding war, with Netflix (NSDQ:NFLX) securing an initial deal for key assets and Paramount Global (NSDQ:PARA) launching a hostile takeover bid for the entire company. It almost feels like a poker match, Paramount holding pocket aces and Netflix sitting…

ByCharlie YouldenDecember 9, 2025

Ovanti (ASX: OVT) Partners with Mastercard’s Finicity as US BNPL Strategy Takes Shape

Ovanti (ASX: OVT) has secured a partnership with Finicity, a Mastercard company, to power its upcoming buy‑now‑pay‑later platform in the United States. This marks the third major deal in 2025, following agreements with payment processor Shift4 and lending platform BNPLPay, and completes Ovanti’s US partnership stack ahead of the planned Flote launch in Q1 2026.…

ByUjjwal MaheshwariDecember 9, 2025

China’s New AI IPO Moore Threads Skyrockets 425% on Debut

Moore Threads Soars 425% on Debut as Investors Chase the Next Nvidia It’s starting to look like any company with an AI label in China can trigger enormous rallies, as the country pushes aggressively to rival US dominance in artificial intelligence. Despite China already being ahead in several AI applications, investor enthusiasm has gone into…

ByCharlie YouldenDecember 8, 2025

Telix Pharmaceuticals (ASX:TLX) Back on Track, First Patient Dosed in Phase 3 PROSTACT Trial

TLX Delivers Clinical Progress It’s good to finally see some positive news from Telix Pharmaceuticals (ASX:TLX) after a relatively quiet period, especially following recent market nerves around the FDA slowdown and a few ASX announcement missteps. Today, the company reported an important milestone in its PROSTACT Global Phase 3 trial, confirming that the first patient…

ByCharlie YouldenDecember 8, 2025